Leverkusen
(pta/07.06.2021/15:50 UTC+2)
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021.
The Company's preliminary, unaudited revenue from product sales in May 2021 amounted to approximately EUR 2,437 thousand, compared to EUR 1,172 thousand in May 2020, an increase of 108%.
Preliminary revenues from product sales in the US were around EUR 1,638 thousand compared to EUR 599 thousand in May 2020, an increase of 174%. In Germany, revenues from product sales amounted to approximately EUR 425 thousand, compared to EUR 540 thousand in May 2020, a decrease of 21%. Despite the pandemic, sales in Germany had developed positively last year, and in May in particular, we saw catch-up effects from the lock-down month of April 2020. In the rest of Europe, the Company generated product sales of around EUR 374 thousand, compared to EUR 33 thousand in May 2020, a plus of 1,041%.
Preliminary unaudited revenues
in EUR thousands | May 2021 | May 2020 | May 2019 | January - May 2021 | January - May 2020 | January - May 2019 |
USA | 1,638 | 599 | 1,764 | 7,288 | 5,112 | 8,702 |
Germany | 425 | 540 | 419 | 2,272 | 1,993 | 1,844 |
Europe (ex Germany) | 374 | 33 | 241 | 867 | 869 | 996 |
Total revenue from product sales | 2,437 | 1,172 | 2,424 | 10,427 | 7,975 | 11,543 |
Revenues from R&D projects and license payments | 0 | 120 | 64 | 0 | 6,392 | 108 |
Total revenue | 2,437 | 1,292 | 2,488 | 10,427 | 14,367 | 11,651 |
(end)
Emitter: |
Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany |
![]() |
---|---|---|
Contact Person: | Investor Relations | |
Phone: | +49 (0) 214 87 63 20 | |
E-Mail: | ir@biofrontera.com | |
Website: | www.biofrontera.com | |
ISIN(s): | DE0006046113 (Share) | |
Stock Exchange(s): | Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate | |
Other Stock Exchanges: | Nasdaq |